AbbVie Acquires Global Rights to ISB 2001 in $700M Deal

Published on LinkedIn via Spencer Knight

AbbVie has secured worldwide rights to ISB 2001, a first-in-class trispecific antibody developed by IGI, targeting CD38, BCMA, and CD3 for relapsed or refractory multiple myeloma. The deal includes a $700 million upfront payment and over $1.2 billion in milestones. Early trial data show a 79 percent response rate and 30 percent complete responses in heavily pretreated patients. ISB 2001 is designed to overcome antigen escape and represents AbbVie's strategic bet on trispecifics as the next wave in T-cell engagement.

Read the full article on LinkedIn:

👉 AbbVie pays $700M for IGI’s trispecific multiple myeloma therapy

Images used are for illustrative purposes only and do not depict actual persons, products, or facilities. For full detail, refer to the original article via the provided link.